Allison Hoch
Director AbbVie
Allison Hoch is with Global Alliances at AbbVie and supports 5 alliances with assets ranging from discovery to commercial. Before this, she was at Morgan Stanley healthcare investment banking, helping biotech companies raise capital. She has also held roles in research, commercial and medical affairs in large pharma and mid-cap biotech. She has a PhD in bioengineering and an MBA.
Seminars
Thursday 29th January 2026
Panel Discussion: Unlocking Biotech-Pharma Collaboration: How Agile Small Teams & Experienced Pharma Combine Strengths to Accelerate Innovation & Deliver Real-World Impact
2:00 pm
This panel will discuss collaboration in delivery development i.e., co-developing platforms, managing device timelines, and regulatory alignment in combo products.
- Strategies to leverage the speed and innovation of biotech startups alongside the deep experience and resources of pharma giants like AbbVie: turning potential clashes into powerful synergies
- What “we’re thoroughly enjoying our AbbVie relationship” means in practice: how both Ripple Therapeutics and AbbVie have fostered continuous learning and development through close cooperation during diligence, development planning, and execution phases
- The importance of proactive, transparent communication, and collaboration across functions, including early alignment with device teams and other stakeholders, to anticipate challenges and optimize program success
